Prostate Cancer

Case summary:

Jose C. is a prostate cancer patient who came to us through his wife, looking for a treatment alternative that could help him fight the disease.

When we reviewed the documentation of the case, we were able to confirm that it was an acinar adenocarcinoma of the prostate with possible metastasis in the pelvis. José had a constant bladder catheter for urine output.

Once the case had been analyzed by our specialists, we informed the family what they could expect with Escozul™ and the possibilities of achieving good results. Generally, in cases of prostate cancer, the results are positive in most patients, helping at least to control the disease.

Each dose of Escozul™ is personalized, specific to the type and aggressiveness of the tumor. These doses can change over time according to the results observed in the patient. This requires an effective communication between the patient and our medical team to allow us to make the appropriate recommendations on different aspects. If the patient or family members do not maintain fluid communication with us, then the results with Escozul™ will not be as expected.

José started treatment with Escozul™ in November 2017, he was on treatment with Cyproterone.

Evolution, Follow-up and Current Results:

Since the beginning of the treatment, José C's wife has been in contact with the doctor in charge of the case by LifEscozul™ to keep reporting the progress José has had with the treatment. At the end of December 2017 she indicated to us that the PSA had begun to decrease.

In the month of February 2018 he contacted us again indicating a new decrease in the PSA value and again the same result was obtained in April:

PSA VALUES BY MONTH

October 2017--------- 116

December 2017-------- 76.6

January 2018 ---------- 38.3

April 2018 ---------- 21.3

As we can see PSA has been progressively decreasing, indicating a decrease in carcinogenic activity.

In May 2018 we were informed that finally, after one year, it was possible to remove Jose's bladder catheter and that his urologist is assessing a possible surgery once the PSA values normalize. This represents, first of all, a considerable improvement in José's quality of life, as he can finally do without the bladder catheter for urination; furthermore, the possibility of surgery represents the option of being able to eliminate the tumor lesions in the prostate and considerably improve his expectations of evolution and survival.

José C. continues to be treated with Escozul™ with progressive dose increases, with the objective of maintaining and improving the results obtained up to now.

As we always say, it is important to point out that it is not possible to generalize any result with Escozul™ to avoid creating false expectations in people, Escozul™ does not work miracles. Only working together and constant communication allow to keep the doses of Escozul™ personalized and functional against tumors.

It is also important to say that all the medical information of the case is available for consultation, as well as the contact with the medical counterpart of both the oncologist who attended the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

If you wish to be treated under the Escozul™ Protocol, you should know the following: Escozul™ is a product that we are still investigating, including its other properties such as analgesic and anti-inflammatory, therefore it is not a commercial product, i.e. it cannot be sold. Each case that wishes to enter our protocol must be evaluated and approved because Escozul™ is not effective in all types of tumors. Once approved, the patient and his family members must commit to maintain a fluid contact with our medical team.

To enter the protocol you must send us an email to: servicios@lifescozulcuba.com indicating the patient's age, the type of cancer and the patient's physical and emotional state. This is the first step, and a specialist will take charge of the case. Our response time is an hour or two because each case is answered personally, not automatically. The idea is that the communication we establish is always governed by a professional and humane treatment.

Prepared by LifEscozul™ Group May/2018

Medical Documents

Initial Diagnosis:

Prostate cancer. PSA values: 16.6 (normal value up to 4). This antigen determines the level of tumor activity.

Patient's condition before starting treatment:

- Acute fatigue.

- Pain in the prostate area up to the anal region.

Analysis to determine dose and concentration of Escozul™:

The case is evaluated by analyzing the type of cancer, its stage, aggressiveness, treatments applied and response. The physical and psychological condition of the patient is also taken into account.

A copy of this evaluation is sent to the patient and his/her family. It starts with Escozul™ in September 2014, with prescription of doses according to the progression of the disease and the patient's symptoms.

Escozul™ is a natural product that has the ability to eliminate tumor cells without meaning that it is a cure for cancer. Its ability to inhibit malignant cell growth allows it to be used as a disease controller and the focus of work is done looking for the patient to be able to live with his disease with the least possible affectation to his daily routine. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717326/

Current results:

After 3 months of treatment, these are the main results:

• He refers to feeling very well, with total improvement of symptoms.
• PSA value decreased to 1.2*** below the cut-off value.

The dose was adjusted according to the results in order to continue with the treatment and maintain and improve the results obtained.

Summary:

During the treatment time, the patient's symptoms have improved and PSA parameters have decreased. The results obtained in this case, are among the best presented in the treatment of prostate cancer patients, it is among the 30% of patients who have a rapid response to the drug.

The result is considered positive, since it has been achieved in a very short time, reducing the antigen value to normal levels and improving the patient's symptomatology. It should be emphasized that the contact between the patient and our medical team had a decisive influence in achieving these results, since it allowed adjustments to be made to the dose, which in turn had an impact on the disease.

Medical Documents

Initial Diagnosis:

Prostate cancer (acinar adenocarcinoma Gleason 6 (3 plus 3) in right side of prostate), tumor marker PSA=7.19, in July 2013 (normal value up to 4).

Patient's condition before starting treatment:

- Pelvic discomfort (lower abdomen).

Treatments:

Started treatment with Escozul™ in October 2013. She was prescribed a dose according to her type of cancer and condition, also considering the non-application of other oncological treatments.

Escozul™ is a natural product that has the ability to eliminate tumor cells without meaning that it is a cure for cancer. Its ability to inhibit malignant cell growth allows it to be used as a disease controller and the focus of the work is done so that the patient can live with his disease with the least possible impact on his daily routine. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717326/

Prostate cancer in particular, especially if it has not metastasized, generally has a good response to treatment with Escozul™, and the least that is achieved is to prevent the progression of the disease. Given his age, the patient declined the option of surgery.

Case evolution:

Subsequent to the initiation of treatment with Escozul™, the antigen began to decrease. The patient then opted to start, in addition to Escozul, radiotherapy, which proceeded without major consequences or discomfort.

Current Results:

In October 2014, one year after treatment with Escozul™, the patient was in good physical condition, performing his daily activities, without any symptoms of disease progression. A reduction of the PSA antigen value to 1.8 was achieved, after the first year of treatment (within normal values). Patient Jose has been on Escozul™ treatment since 20013, with a 6-month break in 2016. His results have remained within normal limits and his doctors find him getting better and better. There is no sign of disease progression.

Summary:

The patient has been able to have a good quality of life and the cancer activity in the body has been kept under control, lowering the tumor marker value from 7.19 to 1.8, which is within normal values.

The use of Escozul™ has allowed José to continue living a normal life and enjoying his family, without any symptoms. Even though all his parameters are normal, Jose remains on treatment with Escozul™, to prevent any relapse of the disease.

Medical Documents

Initial Diagnosis:

Prostate cancer (acinar adenocarcinoma).

Patient's condition before starting treatment:

• - Lower abdominal discomfort.
• - Frequent nocturnal urination
• - Incomplete urination

Analysis to determine dose and concentration of Escozul™:

The case is evaluated by analyzing the type of cancer, its stage, aggressiveness, treatments applied and response. The physical and psychological condition of the patient is also taken into account.

A copy of this evaluation is sent to the patient and his/her family. Escozul™ is started in January 2012, with doses prescribed according to the progression of the disease and the patient's symptoms. Escozul™ doses were gradually increased during the first months of treatment, until the disease was brought under control.

Escozul™ has the ability to selectively eliminate cancer cells without affecting healthy cells, which leads to tumor growth control and even tumor shrinkage, as well as helping to improve the patient's quality of life. It acts on many types of cancer, with better results in solid tumors, the effectiveness depends on the type of cancer and the degree of disease progression. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717326/

Current Results:

The prostate has decreased in size, the patient has no symptoms of cancer, and after almost 3 years of treatment with Escozul™ alone, no examination has reported presence of bone metastases, nor tumor enlargement.

Summary:

The patient's results are considered very positive since the disease has been stabilized and the symptoms have been eliminated, which leads to an improvement in the patient's quality of life and an increase in his life expectancy, in addition to the fact that the patient leads an active life in all senses and without limitations. It should be emphasized that the contact between the patient and our medical team had a decisive influence in achieving these results, since it allowed adjustments to be made to the dosage, which in turn had an impact on the disease.

Medical Documents